ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: TH-PO662

The Difference Between eGFR by Cystatin C vs. Creatinine Provides Clinical Information About Frailty in CHS

Session Information

  • Geriatric Nephrology
    November 07, 2019 | Location: Exhibit Hall, Walter E. Washington Convention Center
    Abstract Time: 10:00 AM - 12:00 PM

Category: Geriatric Nephrology

  • 1100 Geriatric Nephrology


  • Potok, O. Alison, UCSD, San Diego, California, United States
  • Katz, Ronit, University of Washington, Seattle, Washington, United States
  • Bansal, Nisha, Kidney Research Institute, Seattle, Washington, United States
  • Siscovick, David, University of Washington, Seattle, Washington, United States
  • Ix, Joachim H., UCSD, San Diego, California, United States
  • Shlipak, Michael, San Francisco VA Medical Center, San Francisco, California, United States
  • Rifkin, Dena E., UCSD, San Diego, California, United States

Kidney function is typically assessed using serum creatinine. Cystatin C is an alternative marker of kidney function. The clinical significance of having a difference in estimated glomerular filtration rate (eGFR) by these 2 measures is unknown. We hypothesized that the magnitude of this difference is associated with frailty.


In 4101 community-dwelling older adults from the Cardiovascular Health Study (CHS) cohort, we investigated the cross-sectional association of the difference in eGFR by cystatin C vs. by creatinine (eGFRDiff) at baseline with prevalent frailty, using logistic regression, and the longitudinal association of eGFRDiff with incident frailty and mortality at 5 years, using Poisson regression. eGFR was calculated using CKD-EPI equations based on either measure (eGFRCr and eGFRCys respectively), and eGFRDiff was eGFRCys - eGFRCr. Frailty was assessed based on the Fried frailty score.


Mean (±SD) age was 72 (±5) years, eGFRCr was 73 (±17) and mean eGFRDiff was -1.4 (range -68.0 to 70.6) mL/min/1.72m2. 39% were males, 5% African-American, 72% non-diabetics. Per 10-point increment in eGFRDiff, the prevalence of moderate frailty was 19% lower, and that of severe frailty was 36% lower, in fully adjusted model (Table 1). Higher eGFRDiff (per 10 mL/min/1.73m2) was associated with lower incidence rate ratio for moderate (IRR 0.93, 95%CI [0.87; 0.99]) and severe (IRR 0.59, 95%CI [0.47; 0.74]) frailty, as well as lower risk of mortality (IRR 0.65, 95%CI [0.57; 0.76], p<0.0001).


Those with a lower eGFRCys than eGFRCr were more likely to have prevalent frailty and were at higher risk for incident frailty and mortality. Considering eGFRDiff as a marker of patients’ functional status may be a useful clinical tool to assess important geriatric outcomes.

Association of eGFRDiff (per 10-point increment) with frailty at baseline
Outcome: Frailty (n = 2084)Moderately Frail (n=1832)Severely Frail (n=252)
 OR (95% CI)p valueOR (95% CI)p value
Unadjusted0.78 (0.74; 0.82)<0.00010.64 (0.58; 0.71)<0.0001
Fully adjusted *0.81 (0.76; 0.85)<0.00010.64 (0.57; 0.72)<0.0001

*adjusted for age, gender, race, body mass index, hypertension, diabetes, anti-hypertensives at baseline, cholesterol, smoking, chronic kidney disease stage by eGFRCr


  • Other NIH Support